乐普医疗(300003) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 2,437,202,386.92, a decrease of 4.39% compared to CNY 2,549,111,243.52 in the same period last year[4] - Net profit attributable to shareholders increased by 9.45% to CNY 596,924,222.49, up from CNY 545,393,656.31 year-on-year[4] - The net profit for the first quarter of 2023 was CNY 618.32 million, an increase of 10% compared to CNY 562.13 million in the same period last year[21] - The total comprehensive income attributable to the parent company was CNY 638.69 million, up from CNY 419.81 million year-on-year[22] - Basic earnings per share increased to CNY 0.3205 from CNY 0.3054 in the previous year, reflecting a growth of approximately 6.8%[22] - Operating profit for the quarter was CNY 699.84 million, slightly up from CNY 684.52 million in the same quarter of the previous year[21] Cash Flow and Liquidity - The net cash flow from operating activities showed a significant decline, with a net outflow of CNY 134,203,435.01, a decrease of 129.89% compared to a net inflow of CNY 448,932,891.19 in the previous year[4] - Cash and cash equivalents at the end of the period were CNY 5,297,999,204.12, a decrease of 3.1% from CNY 5,467,278,785.39 at the beginning of the year[18] - Cash and cash equivalents at the end of the period were CNY 5.17 billion, down from CNY 3.53 billion at the end of the previous year[24] - Investment activities resulted in a net cash outflow of CNY 212.41 million, an improvement from a net outflow of CNY 436.73 million in the same period last year[24] - The company experienced a foreign exchange loss of CNY 42.62 million, impacting the overall cash position[24] Assets and Liabilities - The company’s total assets at the end of the reporting period were CNY 24,559,902,516.86, reflecting a slight increase of 0.31% from the previous year[4] - Total liabilities decreased to CNY 7,477,548,984.26, down from CNY 8,113,549,880.82 at the beginning of the year[19] - The company's equity attributable to shareholders increased to CNY 15,823,636,468.24, compared to CNY 15,146,202,761.30 at the beginning of the year[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 83,934, with the top ten shareholders holding a combined 60.94% of shares[12] - The largest shareholder, China Shipbuilding Industry Group Company, holds 12.98% of shares, totaling 244,063,788 shares[12] - WP Medical Technologies, Inc. is the second-largest shareholder with 12.13%, holding 228,074,749 shares[12] - The top ten shareholders include various investment funds and individuals, with the largest being state-owned entities and private investors[12] - The company has a significant portion of shares pledged, with 171,056,062 shares pledged by shareholder Pu Zhongjie[14] Operational Highlights - The cardiovascular intervention product line achieved positive growth despite a general decline in sales, with the medical services and health management segment growing by 16.06% year-on-year[8] - Research and development expenses increased to CNY 229,686,257.30, up 8.1% from CNY 212,393,810.51 in the previous year[20] - Total operating costs decreased to CNY 1,749,019,988.44, down 5% from CNY 1,840,886,155.20 year-over-year[20] - Gross profit margin improved to approximately 28.3%, compared to 26.5% in the previous year[20] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[20]